Novartis Backs mRNA Platform With $575 Million Upfront as Pipeline Setbacks Mount
Published on 10/04/2026 at 00:30 | Editorial boerse-global.de
Novartis has moved to shore up its clinical development pipeline through a global licensing and option agreement with Abogen Biosciences, securing worldwide rights to the mRNA-encoded T-cell engager ABO2203 alongside exclusive options on additional RNA-based programs from the partner's platform.
The deal, struck yesterday, carries a $575 million upfront payment to Abogen. Should all contractual options be exercised and development milestones be met, success-based payments could reach roughly $7.2 billion, with Reuters pegging the total potential value of the arrangement — including every component — at up to $7.8 billion. The development program is designed to target potential applications including autoimmune diseases, according to the news agency.
Filling Gaps After a Bruising September
The tie-up comes against a difficult stretch for the Basel-based group's late-stage research. Two Phase III programs stumbled in September: the HARBOR study of del-desiran missed its primary endpoint, and just days earlier the Lp(a)HORIZON trial of pelacarsen failed to hit its primary goal. Expanding collaboration with external biotech firms is intended to close the holes in the project pipeline over the longer term, while the access to Abogen's RNA platform adds development candidates that push Novartis's clinical reach beyond its established core areas.
Should investors sell immediately? Or is it worth buying Novartis?
Progress in existing programs has continued in parallel. Roughly two weeks ago, Novartis received a positive CHMP opinion for Cosentyx in polymyalgia rheumatica, setting the stage for a final approval decision in that indication. On the governance front, chairman Giovanni Caforio signed an open letter on 22 September together with the heads of eight other pharmaceutical companies, addressing Europe's competitiveness in drug research and investment in innovation.
Market Reaction Muted
Investors took the licensing news in stride. The stock closed Friday's European session at EUR 125.16, a modest daily decline of 0.4%, and remains below its 52-week high of EUR 144.30. Year to date, the shares are up 5.9%.
Analyst activity picked up during the week as well. On 1 October, Goldman Sachs kept its "Sell" rating on Novartis but lifted its price target to CHF 113 from CHF 110 — a stance the research house had already maintained on 22 September.
Third-Quarter Report on the Horizon
Attention now shifts to the company's financial calendar. Novartis will publish results for the third quarter and the first nine months of the current fiscal year on 27 October 2026. Only with that interim report are more detailed insights expected into how the recent trial outcomes and licensing agreements are shaping the group's financial outlook and current research momentum.
Ad
Novartis Stock: New Analysis - 4 October
Fresh Novartis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
